Published: Feb. 22, 2021 at 11:05 a.m. ET
By Tonya Garcia
CVS says COVID testing and vaccinations will put the company in contact with millions of new customers.
CVS Health Inc. CVS, -0.21% is looking forward to the chance to meet tons of new shoppers in the coming months as it administers the COVID-19 vaccine, offering the pharmacy retailer a unique business opportunity.
CVS has provided COVID-19 testing, with about 15 million tests administered at its 4,800 locations across the country, according to Karen Lynch, chief executive of CVS.
The pharmacy retailer has also launched a program, Return Ready, designed to help companies and universities prepare for the return of workers and students, with 100 clients enrolled.
The federal government selected CVS to administer COVID vaccines at long-term care facilities, administering more than three million doses to patients and workers. By mid-March, CVS says it will have administered both doses of the vaccine at assisted-living facilities.
As part of President Joseph Biden’s COVID vaccination plan, CVS will administer 250,000 COVID immunizations across 11 states.
“Millions of new customers will engage with CVS Health for the first time through testing and vaccine administration services,” Lynch said during last week’s earnings call, according to FactSet.
“It will create the opportunity to expand our customer base, while deepening relationships with current customers.”
Truist analysts say there are a few factors that set CVS up for gains, including “market pressures, rising patient consumerism and increased demand for de-centralized care.” Expanding access to low-cost care through MinuteClinic and expanding its virtual care offering are just a couple of examples.
“The company’s meaningful COVID testing/vaccine response is offering
additional patient connectivity (most signing up digitally), broadening the new customers playing field and we see the potential for additional acceleration as vaccine distribution further ramps,” David MacDonald said.
Truist rates CVS stock buy with an $80 price target.
Even with all of the interaction CVS says COVID-19 “is expected to have an immaterial impact” on 2021 adjusted earnings per share.
How can that statement be true? - FUNMAN
CVS reported a fourth-quarter EPS and adjusted EPS decline, though results beat the FactSet consensus. Higher revenue also beat the FactSet consensus.
“COVID-19 is expected to have a benefit to the retail/long-term care segment and have an unfavorable temporal impact to the health care benefits segment,” Eva Boratto, CVS’ chief financial officer, said on the earnings call.
JPMorgan analysts note that COVID-19 was a 25-cents-per-share net adjusted EPS tailwind in 2020.
“Within the retail/long-term care segment in 4Q, the company pointed to lower pharmacy volumes from a reduction in new therapy prescriptions, including fewer seasonal flu prescriptions, reduced front store traffic and volume from a lower cough/cold/flu season, incremental costs ahead of vaccine administration, and benefits from diagnostic testing,” analysts said.
Very interesting. - FUNMAN
Still, JPMorgan thinks the company is well-positioned for a future that includes new reimbursement models, the “retailization” of healthcare, and the need for cost savings.
“We continue to believe the ability to leverage medical, pharmacy and lab data to target interventions, improve member engagement to drive behavior change, and drive care to lower cost settings will drive improved quality of care, better outcomes and lower overall healthcare costs, which will ultimately drive profit growth,” analysts said.
JPMorgan rates CVS shares overweight with a $102 price target.
Nice - FUNMAN
Watch: How telehealth could become a $175 billion market in the next 5 years
Mizuho analysts are also upbeat about the increasingly diverse nature of CVS’ business. Moreover, as the COVID pandemic comes to a close, colds and the flu should make a return.
“The weak cold/flu season is expected to continue in 1Q:21 and likely 4Q:21,” Mizuho said. “We view this a transitory issue that should normalize in 2022.”
Mizuho rates CVS stock buy with an $82 price target.
CVS shares are up 4.7% over the past three months, but have fallen 2.8% over the last year. The benchmark S&P 500 index SPX, -0.22% has gained 16.4% over the last 12 months.
Recent CVS News
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 09/19/2024 09:29:08 PM
- CVS Health announces quarterly dividend • PR Newswire (US) • 09/19/2024 03:02:00 PM
- CVS Pharmacy® launches birth control prescribing in Massachusetts • PR Newswire (US) • 09/12/2024 01:00:00 PM
- CVS Health supporting customers, patients, members and colleagues as Tropical Storm Francine approaches • PR Newswire (US) • 09/10/2024 07:43:00 PM
- Shareholders of CVS Health Corporation Should Contact The Gross Law Firm Before September 10, 2024 to Discuss Your Rights - CVS • PR Newswire (US) • 09/09/2024 02:32:00 PM
- The Gross Law Firm Notifies CVS Health Corporation Investors of a Class Action Lawsuit and Upcoming Deadline - CVS • PR Newswire (US) • 09/05/2024 09:45:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/03/2024 09:47:27 PM
- CVS Health Corporation Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm for More Information - CVS • PR Newswire (US) • 08/29/2024 10:05:00 AM
- Updated flu and COVID-19 vaccinations now available at CVS Pharmacy® and MinuteClinic® • PR Newswire (US) • 08/28/2024 12:00:00 PM
- Aetna first major insurer to expand and simplify access to fertility services • PR Newswire (US) • 08/27/2024 12:00:00 PM
- Class Action Filed Against CVS Health Corporation (CVS) Seeking Recovery for Investors - Contact The Gross Law Firm • PR Newswire (US) • 08/26/2024 09:45:00 AM
- Shareholders of CVS Health Corporation Should Contact The Gross Law Firm Before September 10, 2024 to Discuss Your Rights - CVS • PR Newswire (US) • 08/22/2024 09:45:00 AM
- CVS Pharmacy® introduces colleague-designed journals • PR Newswire (US) • 08/21/2024 12:00:00 PM
- CVS Health Corporation Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm Before September 10, 2024 to Discuss Your Rights - CVS • PR Newswire (US) • 08/19/2024 09:45:00 AM
- Google Mandated to Modify Play Store, Apple Innovates, Victoria’s Secret Hires CEO, Mars Buys Kellanova • IH Market News • 08/15/2024 10:05:46 AM
- Google Forced to Modify Play Store, Apple Innovates, Victoria’s Secret Hires CEO, Mars Buys Kellanova • IH Market News • 08/15/2024 10:05:46 AM
- CVS Health Corporation Class Action: The Gross Law Firm Reminds CVS Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of September 10, 2024 - CVS • PR Newswire (US) • 08/15/2024 09:45:00 AM
- CVS Health Names Heidi Capozzi Executive Vice President, Chief People Officer • PR Newswire (US) • 08/14/2024 08:00:00 PM
- CVS Health Foundation joins forces with organizations at City Center to improve health outcomes in Fresno • PR Newswire (US) • 08/14/2024 05:00:00 PM
- AM Best Revises Issuer Credit Rating Outlooks to Stable for Most of CVS Health Corporation’s Aetna Inc. Subsidiaries • Business Wire • 08/14/2024 02:39:00 PM
- Class Action Filed Against CVS Health Corporation (CVS) - September 10, 2024 Deadline to Join - Contact The Gross Law Firm • PR Newswire (US) • 08/08/2024 09:45:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/07/2024 10:35:29 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/07/2024 10:33:48 AM
- CVS HEALTH CORPORATION REPORTS SECOND QUARTER 2024 RESULTS AND REVISES FULL-YEAR 2024 GUIDANCE • PR Newswire (US) • 08/07/2024 10:30:00 AM
FEATURED Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • Sep 24, 2024 8:50 AM
FEATURED Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM